Q4 2019 Earnings Call
Greetings and welcome took care of Dx incorporated fourth quarter financial results Conference call. At this time all participants are in listen only mode. A question answer session will follow the formal presentation.
Anyone should require operator assistance during the conference. Please press star zero on your telephone keypad.
Please note this conference call is being recorded.
I'd now like to turn the conference over to your host Greg.
I'll check managing director. Thank you you may begin.
Good afternoon, and thank you for joining us today earlier today cardiac released financial results for the quarter and your ended December 31st 2000 like Pete.
Releases currently available on the company's website at Www Dot care Dx Dot com.
Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer will host this afternoons call.
Before we get started I will like to remind everyone that management will be making statements. During the call that include forward looking statements within the meaning of the federal Securities laws, which are made pursuant to the safe Harbor provisions of the private Securities Litigation Reform Act of Nike 95.
Any statements contained in this call that are not statements of historical fact should be deemed to be forward looking statements.
All forward looking statements, including without limitation or examination of historical operating trends expectations regarding coverage decisions pricing and enrollment matters in our future financial expectations on results are based upon current estimates at various assumptions.
These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward looking statements.
Accordingly, you should not place undue reliance on these statements.
For a list and descriptions of these are the risks and uncertainties associated with our business. Please see our filings with the Securities Exchange Commission.
The information provided in this conference call speaks only to the light broadcast today.
If you worry 27th 2020.
Care Dx disclaims any intention or obligation, except as required by law to update or revise any information financial projections or other forward looking statements, whether because of new information future events or otherwise.
This call will also include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles.
Reconciliation to the most directly comparable GAAP financial measure maybe found in today's earnings release filed with the FCC I'll now turn the call over to Peter.
Thanks, Greg and good afternoon, everyone I'm pleased to welcome you to the care Dx called reviewing our results for the fourth quarter and full year 2019, before we dive into the results I wanted to highlight Robert Montgomery. Many of you may have seen the news flow on Rob a kidney transplant surgeon, who recently received.
The heart transplant himself, Rob is not only using allomap and other short for his heart transplant. So they didn't but he will also be speaking at the upcoming see I'd conference and introduced our immune optimization study called Cuba.
It is for patients and conditions like Rob that we at Caredx I coming to work every day together with a transplant community. We have built a tremendous platform in transplantation over the last 20 years.
Now turning to resolve 2019, but a very exciting year for cardiac as continued momentum for our high value health care solution for transplant patients and caregivers drove robust revenue growth.
Our full year revenue, what 127.1 million, representing 66% growth over the prior year and clearly exceeded our most recent guidance range of 100, then 24 to 125 million.
For the fourth quarter of 2019 total revenue was 35.8 million, increasing 52% to compare to the year ago quarter.
The majority of the growth in the quarter came from our testing services revenue, which increased 55%.
Product revenue for the quarter was 5.1 million and digital revenue added 1.6 million to the topline.
Well, that's again posting positive adjusted EBITDA in the fourth quarter, we feel very comfortable about the execution of our plan to build a powerful platform in transplantation.
Nobody else has never been stronger.
Digging deeper into our testing services for the fourth quarter Qt ex provided 14055, other short kidney and Allomap hard for South to address then patients in the quarter growing 63% from the 8632.
Resolved in Q4 2018.
Since launching in October 2018 over 150 centers have provided I look forward thoughts to their kidney transplant patients by end of 2019 over 30 transplant centers in the United States had adopted an olive short testing protocol into their standard of care.
We are pleased to announce that enrollment in our kidney allograft outcomes oller sure registry or key or study is nearly completed we have a total of 55 centers in the study the study called for a thousand 500 patients to be monitored using our Aldo show protocol or 15 test over three years. So.
For the next three years. The study centers will continue to observe transplant patients for kidney allograft issues and patient data will continue to be mind provide insights driving the field for.
Just recently, we announced that the American journal of transplantation accepted for publication of people title high levels of donor derived cell free DNA identify patients the T cell mediated rejection, one eight and borderline allograft rejection elevated risk off graft injury.
Based on the data presented in this paper, which shows our shores ability to discriminate the clinical relevance of T cell mediated rejection or borderline biopsies.
We believe I'll show the ultimate do change how clinicians kill for transplant patients who have ambiguous rejection based on biopsy.
This study may.
How do you find the true liquid biopsy for transplant medicine.
Turning to our aircraft study across stands for outcomes of kidney care in Reno Allografts, we begin enrolling patients in September 2019 enrollment continues to ramp nicely.
As a reminder, this multicenter prospective observational clinical trial is designed to measure outcomes of kidney transplant recipients managed with kidney care. The combination of donor derived cell free DNA using aloe sure gene expression profiling, using allomap and prognostic graft assessment, you think I bought.
The Okra studies designed to ultimately include 4000 patients, adding in our previous multicenter prospective study.
This gives us an extensive an in depth set of patient outcome over the next five years, we expect significant data and findings from key Orient Okra. These findings will not only be published in peer reviewed journal, but will ultimately lead to changes in the way patients on medically cared for after transplantation for example, based on the anomaly.
<unk> data off the first 7000, K., our sample and the recently published TCM. Our data we were able to identify clinical relevance of our short between the opened 2% and 1% level, which is very exciting since these new insights can directly impact clinical decision, making.
Now shifting to heart Allomap testing volume through solidly in the fourth quarter heart care, the combination of Allomap and others will hard gained great traction in the cardiac transplant community distraction might be driven by our ongoing surveillance heart care outcomes registry or short.
As of December 31st 2019, we had record at 39 cents into the short study.
In the fourth quarter product revenue increased 10% comport compared to the year ago water. We expect our two recently launched products I will seek cell free DNA and Alex seek TX, which created a lot of enthusiasm at our global be decides to start to generate revenue in trended Wendy and to help drive growth globally.
Engine this year and beyond.
Revenue from our digital solutions was 1.6 million fallback water. This revenue was generated from our software solutions, which are used in 84 transplant centers in the U.S. many of which have also adopted other shore allomap or both.
Over the next deal we will continue to extend our digital offerings, including fill the embedding our alisher protocol into transplant vendor in our platform.
I want to take a few minutes to briefly summarize 2019 and offer some thoughts about twentytwenty and beyond I'm very proud off the numerous successes our team has had over the past 12 month.
As we continue to advance security acts as a true trance, then company and that's an essential partner to transplant patients and caregivers.
In 2019, our clinical and marketing teams, but very busy attending and presenting data at eight industry conference.
At the American drew I think Congress in June we showcased 12 abstracts and hosted an incredibly bell attended lunch symposium, which included presentations from seven prominent leaders in transportation during the lunch symposium, we formally announced kidney care. The combination follow clinically validated Allah short testing with Allomap kidney and I box.
Which will deliver personalized and book Nostix solutions for transplantation.
According to many of the clinicians that attended our symposium they not only see value than in identifying when there might be an issue with a drastic patients, but also the possibility of optimizing immune suppression in a rope in a subset of patients.
As many of you know the side effects of immune suppressant I'm not trivial.
For example, they carry the CV risk of infection.
We strongly believe that the ability to personalize the approached the immune suppressant that lead to better outcome and quality of life photographs that patients.
But this approach kill the ex promises to bring precision medicine to the transplant cleaning.
This past November we had a significant presence at the American Society of Nephrology kidney week, we have three abstracts represented on the utility of other short as the surveillance tool and as a marker of out of graft injury.
That all of the conferences, we attended participant turnout at our booth podium presentations and symposium was exceptional.
2019 was also up productive you for our regulatory and reimbursement team as we received regulatory approval and reimbursement wins for both other shouldn't Alamo in February 2019, Alice real became available under the I compassionate use program for lung transplant patients.
In May anthem, Blue Cross of California, and 10 of its affiliated health plans <unk> designated Allomap Heart ethic contracted service, but this change approximately 80% of all insured lives in the U.S. I'm now covered for Alabama.
In August I'm, not sure received a positive draft local coverage determination for Medicare coverage in heart transplant patients demonstrating the value I little can bring to Dr. Stein patient care.
We expect mold ex will make a final coverage decision about other so hard in the second quarter, followed by pricing in the second half of two any trade.
In October 2019, Blue Cross Blue Shield, South Carolina became the first private payer to issue a positive coverage decision on our she'll kidney and we will continue to work hard to expand coverage to even more patients in 2020.
Finally in November we feel the advanced transplant patient care with the launch of Allison <unk> 3.0, our next iteration and continued transplant patient focused improvement. This latest version of other sure provides better care with only one too, but not required better science, but the lowest limit of detection now at opined, one 2% and Ben.
The insights by Stratifying patients with T cell mediated projection.
On the business development front, we feel that our commitment to the drastic community by acquiring order a leading provider of organ transplantation tracking software and Didnt management, a supply off solutions to simplify dress, then quality tracking and weightless management.
We also entered into a partnership with civil Tech for its Iboxx technology and data analysis tool that provides an early prediction often individual risk off Alan Graf projection and transplant loss.
We believe these transactions will not only expand I would direct patient region, but they will also deliver vital analytics to those providing care too fast and patient.
Last but certainly not least in September our commercial team launched I, just think cell free DNA, our kit based donor derived cell free DNA surveillance test and other CTX. The first stuff, it's kind of next generation sequencing easily typing solution utilizing hybrid capture technology.
Now looking ahead 20 trend you should be even more exciting as our pipeline is full our clinical studies are enrolling quickly and providing robots data and we continue to enhance our digital offerings. In 2020, we have several opportunities to continue our rapid growth first and foremost is the continued adoption.
Others for kidney with only 4% penetration of this very large and growing market. We are still at the early stages of adoption.
It's hard we anticipate seeing continued adoption of surveillance protocols for heart care and expect Medicare coverage of other Schweinhart later in the year.
With our products business, we are excited about our newly launched Alice CTX, and obviously cell free DNA product and our ability to accelerate our business overseas.
And he trendy will also security actually spend into stem cell and cellular therapies with our aloe heme at Atlas seek HCT offerings.
Finally, we plan to expand our digital offerings by launching Aloe care, our tool for kidney transplant patients, which will be aimed at improving and enhancing patient engagement.
Everything we do at Caredx has one focus and that is to be the leading partner for transplant patients and advanced and ecosystem with leading the on of the gift campaign Qt exit supporting the community in extending Medicare coverage for immune suppressive medication.
Overall, we continue to receive positive news from HHS and the kidney health initiative.
It's great to see transplantation being the news and even being singled out in the residential addresses and maybe more importantly health care budget.
Community Nephrologists large dialysis providers and advance then community are coming together to increase the number of kidney transplant.
It has never been a better time for cardiac to be a transplant focused company.
With that I will turn the call over to Mike to discuss our financials and.
Twentytwenty guidance.
Thank you Peter.
Turning first to the income statement.
Fourth quarter 2019 testing services revenue increased 55% year over year to 29.1 million.
The growth in the fourth quarter testing services revenue was primarily driven by other show kidney patient results. Although we did experience to lift in Allomap hop testing, partly due to transport senses excitement over hanukkah and the use of surveillance protocols.
Our fourth quarter product revenue increased 10% year over year to 5.1 million and our digital revenue was 1.6 million.
Our gross margins continue to improve year over year.
For the fourth quarter of 2019, the gross margin was 65% compared to a gross margin of 55% in the same period of 2080.
On a sequential basis, the gross margin was down slightly from the third quarter due to fluctuations in our estimated reinvestment rates father shortened allomap, which moved slightly Apollo down each quarter.
The non-GAAP gross margin for the quarter of 68% compared to 59% in the probably a quota.
It's worth highlighting that the non-GAAP gross margin for the testing services business for the three months ended December 31st 29 team has improved to 76% compared to 66% in the same period of 2018.
For the fourth quarters 2019, net loss was 4.8 million compared to a net loss of 3.8 million in the same period of 2018.
Net loss per share was 11 cents for the quarter compared to a net loss per share of nine cents in the fourth quarter of 2018.
For the fourth quarter of 2019, our non-GAAP net income was 1.6 million compared to a non-GAAP net income of zero point Threemillion in the same period of 2018.
Our non-GAAP net income per share in the fourth quarter 2019 was four cents compared to a non-GAAP net income of one cent in the same period of 2018.
As a reminder, we defined adjusted EBITDA as non-GAAP net income before interest income tax depreciation amortization and other expense.
For the fourth quarter of 2019, we recorded six consecutive quarter of positive adjusted EBITDA with a gain of 1.5 million compared to an adjusted EBITDA gain of zero point Eightmillion in the fourth quarter of 2018.
Cash and cash equivalents at December 31st 2019 was 38.2 million.
We continue to hover around the breakeven month for net cash used in operating activities using only 1.1 million of operating cash in the fourth quarter.
Turning to guidance, we're providing our initial twentytwenty revenue expectations to reflect the continued growth about a show as well as steel the growth drivers outlined by pizza.
That's such anticipate 165 to 168 million revenue for the year.
Our guidance does anticipate increased competition and I will show, but balances that with the expectation that additional market entrants will accelerate overall patient penetration.
We feel very well positioned to continue to lead the fields in bringing novel solutions to the Trust Fund clinic.
With that I will open the call for questions.
Thank you at this time will be conducting a question and answer session. If you'd like to ask a question. Please press star one on your telephone keypad.
Hey, confirmation tome indicate your line is in the question Q you May press star to if you'd like to remove your question from the Q.
For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys, one moment, please while we poll for questions.
My first question comes from Bill Quirk with Piper Sandler. Please proceed with your question.
Great. Thank you and good afternoon, everyone.
That's very well how many.
Good first question for me I guess with respect to the 30 transplant centers have incorporated Dallas sure kidney into protocol can't give us a rough estimate in terms of what they represent a with respect to the total market.
Bell Yeah, it's a it's it's Mike here.
I mean, roughly we've focused our.
Our targets on the those centers in the in the top top 100.
Before me census, I'd say that that that's 30, it's representing about.
[noise] about what 20% of the of the total.
Alright, perfect. Thanks, Mike.
And then a couple of an additional questions here like I guess for first off they stay with you and that is philosophically. Thank you for the the revenue guidance, but how to help us think a little bit about some of the puts and takes with respect to operating expenses, which we expect this would be another big ramp up here given the clinical trials and obviously the entrance of competition just just.
Help us better understand how to think about the pacing over the course of there.
Yep.
I would say last year, we had a big ramp up in sales and marketing expense, particularly in the a in the first half of last year.
And we feel on the sounds a must inside now you know where we're pretty much fully fleshed out with a with the sale. So well continue to add to that but we won't see the the huge growth in says a motion expensing twentytwenty. So maybe that's increasing somebody like a <unk> million dollars a quarter your rights on the research and development side, that's probably the area.
Oh, most investment Faros in Twentytwenty, we should see that that research and development expenses continue to grow throughout the year similar to how we grew in the in the last two quarters of a of 2090.
Okay got it and then last one for me and I'll, let somebody else jump on can you talk little <unk>, maybe can you expand on your comments with respect to to private payers. Yeah. We certainly caught the Blue Cross Blue Shield to South Carolina decision, how how active are you talking to other private payers.
And then also does does the guidance or model assume any expansion of coverage. Thank you.
Well. Thank you very much build for the question I think.
The team is focused on engaging payors just as a reminder, 70% to 80% of our patient population all Medicare patient and so private payers are really outside no. We don't see any we don't have modeled into our guidance any significant upside in this year, but the team is continuously working on that's doing a great job.
Having established relationships, but I will now our hartman solution. So there should be some level all oh. This on the other side this year, but there were still thinking that this is very early in the process without only 5% penetration we have ample wasted, though and the only a few centrus we have how critical mass to engage this five appears to make sure that they.
We're also covering.
On patients for their surveillance. So our current guidance is it's not including maybe less below an upside through two private payers on board.
Very good thanks, Peter Thanks, Mike.
Okay.
Our next question comes from Brandon Cool yard with Jefferies. Please proceed with your question [noise].
Thanks, Good afternoon.
Peter Mike maybe a bit of a follow up on on Bill's question. There. She's just talk to us about philosophically, how you approach setting guidance for the year in the context of competition. The degree to which you know the guide kind of handicaps for that dynamic ingenuity any number she can help us with.
Or understand that the the approach.
Well Ben Thank you very much I think our guidance continues to be.
Following our alisha adoption, that's our key need for growth in the company and here, we have seen some linear growth adoption in transportation, which we see also it's you benchmark vessel specialty pharma or although fast plantation products that there is linear adoptions that the solutions are adopted in very.
In the sense that's done this.
We have started extremely strong into twentytwenty and we'll be updating guidance.
FC report on the first quarter again.
So as we were thinking into Twentytwenty, yes, we have the uncertainty around.
In addition, entering the fuel but be just only recently learned learnt that probably their commercial launches are delayed to our previous expectations, which is not reflected in our guidance.
This year again, so no there is the balance all competition coming but also maybe competition expanding our market any leasing the opportunities for accelerated growth in inpatient adoption all surveillance tools, the cell free DNA and especially our store.
Okay, and understanding you're kind of consolidating allomap and al sure volumes charge you report now, but just sort of think about the heart business. In 2020. It would you expect allomap to kind of return to that more normalized mid single digit type growth level, or you think allomap heart or a and C Malhotra heart and.
Some of the surveillance efforts, you're making a can you maybe push set up little bit for the year.
I live might speak to it but you know how hard franchises are working extremely well based on the grades combination now I will not our gene expression profiling tool together with our cell free DNA testing other shore. The short trial is really adopting extremely rapidly. It theres. So many centers in the U.S. excited about.
Joining the call.
So so the heart franchise has been a bid up as a price in 2019, and we are starting 2020 with great momentum, Mike you want to make a comment.
Yeah.
Thanks Peter.
Abundant I'd say I'd say, most specifically you know we still expect the uptake of the surveillance protocols on on Allomap, that's been driven by a by Hanukkah. So you know probably our guidance is is a expectations low low double digit growth.
Them up.
So you know hi, then.
And then the password this low single digit so yeah low double digit growth.
Perfect and then last for me do you expect any major data read outs for the K or study this year.
Perhaps it HTC and any impact on as far as volumes that might be contemplated for now thanks.
Brandon that gives me just put in a block in faulty American general presentation publication on ambiguous rejection, which is really pairing the existing K or initial dataset of more than 7000 samples received on key or together with our inside that.
The Allosure is helpful in the.
Stratification, all contiguous rejection, which is incredibly.
Exciting for us because it helps us tool to not only data on K or patients, but also put it into context of what we learned on the T. CMR the low grade rejection and so yeah. There will continue to be read out there's a tremendous well all abstracts that movie presented at the American fast.
And color.
You know I think cell free DNA and assess the other sure is eating at home from all of innovation in kidney transplantation and security ex being the leader you'll see a lot of outflow all rate clinical data not coming not only out of care, but also out of all the other clinical studies that we currently have ongoing so very.
Side and year for us once youre.
Great. Thank you.
Our next question comes from Alex Nowak with Craig Hallum. Please proceed with your question.
Great. Good afternoon, everyone. Peter you highlighted a number of studies under consideration at the analyst day in January I'm. Just curious have you finalize any of these you know which ones in particular should we be watching and what is incorporated into guide for new clinical studies.
Yes. Thank you very much I think the two studies to watch and see us execute against this year are really all crop, which is the combination of I will not the dollar store together with the buyback eyeball solution, which we call kidney care and a this is a similar afterward I'm.
The going combining the key or study now with the arent study, where we'll have 4000 patients we call it the ultimate kidney transplant registry.
Recruiting in more than 60 centers in the United States Nobel advancing on the.
Recruitment on Oprah and we'll be updating on Oct right in the first of all call. Because this is really for us.
Pivotal clinical trial in the kidney care combination. The second one is kiera I had started the call today.
Lighting, our effort in immune suppressive.
Optimization.
<unk>.
Can you talk about patients. This is a trial, which is very exciting if you think about it.
Sure, it's very very well established already and as a rejection monitoring tool, but maybe Q rise pushing us towards immune optimization.
Ill kidney transplant patients and demonstrating this in a large scale study with multicenter engagement they'll be extremely exciting olysio and demonstrates security excess cutting edge and pushing the envelope. Because this is the Holy Grail in kidney Transplantations Gtx is at the forefront so to summarize our criteria.
At the at the center, but then you see shore S., our heart transplant clinical trial, and then Roar, which is our international filed for South cdna adoption.
Yes, yes as tertiary.
Important now I will also put in a that we are doing clinical studies on cellular therapies or stem cell our outlook in product is extremely promising and be very excited about that pipeline product and that will be detailed says clinical trials.
Okay, great understood and just want to come back and competition and just follow up on brands question are you hearing anything from the physicians you work with specifically around either switching or wanting to join your competitors. Reggie trial, just anything you that you're hearing that made you want to include competition into the guy that this.
<unk> is there anyway to quantify what you're assuming from competition too.
Yes.
I think actually competition has increased the awareness of novel Biomarkers in the field of kidney transplantation. So in a way this is.
Try acuity ex husband Trailblazing, the field and now now there are other engine. So I think this is raising awareness and I actually think that this will be needing to much weaker market adoption going forward.
In terms of very specific Coleman and individual centers, yes, we hear other competitors, placing their registry.
But we haven't seen any substantial clinical adoption of seeing real patients itself being provided in the clinical setting. So I would say that there's maybe noise out there, but it's incredibly difficult to quantify at this stage.
But we feel extremely well positioned with our service offerings.
Well on our short and actually being at home Depot service provider post transplant center, So we feel very well.
No no understood and actually just a follow up on that last piece. There you did ramp up the patient management team over the past 12 months I'm I'm. Just curious are you seeing any change in patient compliance and and how is benefiting alisher I'm your people staying on the Alisher protocol.
Very good question I know you know there are some centers, where we have 99% compliance rate, 90% present compliance rates. I think this is a center, which is absolutely meeting that we see some compliance rates with 55, which has a huge opportunity. If if we are combining that with our patient care management tool now overlaying. This then maybe.
Our software tool, but oh.
Auto offerings.
Sure, it's very convenient to engage patients into long. It you know our clinical trial I think that would be that's that's very beneficial to compare dx and a huge growth opportunity going forward. So.
Add the patient care management, when we have direct interaction that half by in large experian in managing transplantations over long period of time I'm going to get it as a tool increasing compliance and adherence not only to the other shore.
Oh regimen, and political but maybe even for supporting along the judicial patient management forecast that patients going.
Okay got and just last quick question for me, we saw lung study get published on clinical trials like of just where are you add from developing an hour shirt along testing going through the reimbursement process. Thank you.
No. Thank you very much so see submission of lung data. This this year into the molding program.
I think we've we've not been setting timelines and gems of Ben line will be reimbursed. It is somewhat I started opportunity, but lung other short is available today on a compassionate use program and as these clinical trials read out there will be submitting to molding.
This is probably more in terms of a reimbursement that trendy.
21.
Discussion then relevant for revenues in 20 Twond.
Okay understood. Thank you appreciate it.
Thanks next question comes from each and with H.C. Wainwright. Please proceed with your question.
Thank you for taking my question not just to clarify the most recent publication Oh I am sure is going to T to differentiate.
[noise] rejection is based on the original Hello, sure and wish Rose 3.0 is that correct.
It is based on our sure available at that at that stage. So it is combined at our software and other sort of 3.0, depending on which patient was recruited at what stage I don't think that I Wasnt sure one point or 2.03, 0.0 would have any substantial impact on the level.
Measurement on donor derived cell C D.
Okay. So we can assume that the new patients enrolled in the all Chris study, we will have the all I'm sure 3.0, because it's available now.
Oh, Yeah, I know I think going forward any pace. That's currently tested on our school with received the aided us once we file okay. So we shouldn't expect any.
Significant differences in terms of further improvement of the result of using I'm sure 3.0 right.
Well the the clinical without.
The leveled off donor derived cell free DNA level would probably not change no. I think we were talking here about marginal improvements, but more importantly, actually improvements in terms of how the service stations and the patient experience and the sensory experience with.
The lowest level off detection and the ability to differentiate Tc model when a.
Based on the data to be huh.
Got it.
Regarding aloe seek CFP any kit that's sold outside the U.S.
Well, what do you get recorded on the test in lung Orica product revenue line.
Hi.
It's Mike Yes, that's a that's a kit.
And it'll be outside the U.S. and so yeah. When we have revenue for that will start including that in a enough product line. So the product line will be both pre and post transplant and it'll be for that the kit business not the U.S. testing services business.
Got it do you expect any significant gross for all sales outside of your cost of yours.
Well you know a lot of a strategy on the product side and the launch of these products is is to enable us to expand outside the U.S.
I think when we when we look at our auto part of business last year on 2019. The growth was a was overall 10%.
And in a in our guidance, we're looking at the growth now for the product business of.
Of around 20%, so that's coming from the new product launches and again most of you know the I will seek cell free DNA is outside the U.S.. So some of that growth coming from out of the U.S.
Well thank you.
We have reached the end of the question and answer session. At this time I'd like to turn the call back over to Peter Maag for closing comments.
Well I'll keep it short thank you very much for joining this call and I'm looking very much forward too soon update you all about our first quarter results. Thank you very much parties.
This concludes todays conference you may disconnect your lines at this time and we thank you for your participation.